Background/aims: To determine the vitreous levels of soluble vascular endothelial growth factor receptor (sVEGFR)-1 in patients with various vitreoretinal diseases, and to investigate its correlation with patients' age and the activity of proliferative diabetic retinopathy (PDR).
Methods: Vitreous fluid samples were obtained from 187 eyes of 170 patients who underwent vitrectomy for the treatment of idiopathic macular hole (MH, n=30), branch retinal vein occlusion (BRVO, n=37), central retinal vein occlusion (CRVO, n=27), diabetic macular oedema (DME, n=42) and PDR (n=51). The levels of sVEGFR-1 in the vitreous were measured by ELISA.
Results: The levels of sVEGFR-1 (pg/ml) were not significantly different among each disease examined (MH 3900.1 ± 1188.9, BRVO 3969.7 ± 1741.6, CRVO 4897.7 ± 1717.7, DME 3856.21 ± 1374.7, PDR 4212.3 ± 1474.9). There was a significant positive correlation between vitreous concentrations of sVEGFR-1 and patients' age (r=0.430, p<0.01). The sVEGFR-1 concentration in subjects with active PDR was significantly lower than in those with quiescent PDR (p<0.0001), even after being adjusted for age (p<0.0001).
Conclusions: Vitreous concentrations of sVEGFR-1 increase with advancing age and are associated with quiescent rather than active PDR even after adjustment for age.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/bjophthalmol-2011-300139 | DOI Listing |
Indian J Ophthalmol
December 2024
Department of Biochemistry, Trakya University School of Pharmacy, Edirne, Turkey.
Introduction: This study aimed to investigate alterations in intravitreal microRNA and vascular endothelial growth factor (VEGF) levels in patients with proliferative diabetic retinopathy (PDR) as these factors are implicated in PDR pathogenesis.
Methods: Fifty-two participants, including 26 patients with PDR and 26 controls without diabetes, were included in this study. VEGF levels were assessed using ELISA, and seven microRNAs (miRNAs) (miR-19a, miR-20b, miR-27a, miR-124, miR-126-3p, miR-146a, and miR-200b) were analyzed using quantitative real-time PCR.
Mol Ther Methods Clin Dev
December 2024
Clinical Sciences, North Carolina State University, Raleigh, NC 27607, USA.
Non-infectious uveitis (NIU) is a painful recurrent disease affecting 2%-5% of horses. Current treatments require frequent administration with associated adverse events. In a previous study, intravitreal (IVT) adeno-associated virus (AAV) harboring equine interleukin-10 (eqIL-10) cDNA inhibited experimental uveitis in rats.
View Article and Find Full Text PDFTransl Vis Sci Technol
December 2024
Opthea Limited, Melbourne, Victoria, Australia.
Purpose: Sozinibercept inhibits vascular endothelial growth factors (VEGFs) C and D. This study evaluated outcomes following switching from anti-VEGF-A monotherapy to intravitreal injections of three dose levels of sozinibercept in combination with aflibercept in patients with diabetic macular edema (DME).
Methods: A phase 1b, open-label, multicenter dose-escalation study with a 24-week follow-up.
Methods Mol Biol
December 2024
Department of Biochemistry and Molecular Biology, University of Texas Medical Branch at Galveston, Galveston, TX, USA.
Rift Valley fever virus (RVFV) is an important livestock and human pathogen. It is also a potential bioweapon owing to its ability to spread by aerosols. It is an enveloped virus containing surface protrusions composed of two viral glycoproteins, G and G; the viral core contains ribonucleoprotein complexes.
View Article and Find Full Text PDFInvest Ophthalmol Vis Sci
December 2024
Sharon Eccles Steele Center for Translational Medicine, John A. Moran Eye Center, Department of Ophthalmology & Visual Sciences, University of Utah, Salt Lake City, Utah, United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!